Cerebral Infarction: all 817 studies
Page 9 of 9. Open to participants first (182), then studies with results posted, then the rest; newest registration first within each.
- Myocardial Damage In Patients With Cerebral InfarctionCompletedNCT00306579
- ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic StrokeTerminatedNCT00300196Phase 3
- Cilostazol in Acute Ischemic Stroke Treatment (CAIST)CompletedNCT00272454Phase 4
- Investigation of Genetic Risk of Cardiovascular Disease in Prospective Cohort StudyStatus unknownNCT00262691
- Monitoring Brain Activity in Human Brain InjuryStatus unknownNCT00258505
- The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study)CompletedNCT00250380
- Induced Hypertension for Acute Ischemic StrokeCompletedNCT00227448Phase 2
- Efficacy and Safety of Cilostazol for the Indication of CSPSCompletedNCT00216749
- The Threshold Value of Regional Cerebral Oxygenation in Detecting Cerebral IschemiaCompletedNCT00207961
- Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of StrokeCompletedNCT00202020Phase 3
- Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology StudyCompletedNCT00147303Phase 3
- Ancrod (Viprinex™) for the Treatment of Acute, Ischemic StrokeTerminatedNCT00141011Phase 3
- Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)CompletedNCT00129805Phase 3
- PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)CompletedNCT00077805Phase 4
- Vitamin Therapy for Prevention of StrokeCompletedNCT00004734Phase 3
- Aspirin Or Warfarin To Prevent StrokeTerminatedNCT00004728Phase 3
- Antiplatelet Therapy to Prevent Stroke in African AmericansCompletedNCT00004727Phase 4